Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract PARP inhibitors have revolutionized the management of ovarian cancer and are being licenced for other cancer indications. The clinical trials prompting licencing decisions in ovarian cancer were dominated by white participants or participant ethnicity was not documented. To compensate for this, replicative studies like L-MOCA can be run in specific ethnic groups. In future, strategies such as mandatory collection and publication of race and ethnicity data are essential alongside concerted efforts to widen the inclusivity of trial recruitment.

Original publication




Journal article


Clinical Cancer Research


American Association for Cancer Research (AACR)

Publication Date